RU2010102911A - Терапевтический агент для мезотелиомы - Google Patents
Терапевтический агент для мезотелиомы Download PDFInfo
- Publication number
- RU2010102911A RU2010102911A RU2010102911/15A RU2010102911A RU2010102911A RU 2010102911 A RU2010102911 A RU 2010102911A RU 2010102911/15 A RU2010102911/15 A RU 2010102911/15A RU 2010102911 A RU2010102911 A RU 2010102911A RU 2010102911 A RU2010102911 A RU 2010102911A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- mesothelioma
- therapeutic agent
- receptor
- human
- Prior art date
Links
- 206010027406 Mesothelioma Diseases 0.000 title claims abstract 28
- 239000003814 drug Substances 0.000 title claims abstract 27
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract 27
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims abstract 25
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims abstract 21
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims abstract 4
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 claims abstract 4
- 206010035603 Pleural mesothelioma Diseases 0.000 claims abstract 4
- 102000052611 human IL6 Human genes 0.000 claims abstract 4
- 102000005962 receptors Human genes 0.000 claims abstract 4
- 108020003175 receptors Proteins 0.000 claims abstract 4
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 208000006178 malignant mesothelioma Diseases 0.000 claims abstract 2
- 201000005282 malignant pleural mesothelioma Diseases 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mobile Radio Communication Systems (AREA)
Abstract
1. Терапевтический агент для мезотелиомы, который содержит антитело к рецептору интерлейкина-6 (IL-6) в качестве его активного ингредиента. ! 2. Терапевтический агент для мезотелиомы по п.1, где мезотелиома является плевральной мезотелиомой. ! 3. Терапевтический агент для мезотелиомы по п.2, где плевральная мезотелиома является злокачественной плевральной мезотелиомой. ! 4. Терапевтический агент для мезотелиомы по п.1, где антителом к IL-6-рецептору является моноклональное антитело к IL-6-рецептору. ! 5. Терапевтический агент для мезотелиомы по п.1, где антителом к IL-6-рецептору является моноклональное антитело к IL-6-рецептору человека. ! 6. Терапевтический агент для мезотелиомы по п.1, где антителом к IL-6-рецептору является моноклональное антитело к IL-6-рецептору мыши. ! 7. Терапевтический агент для мезотелиомы по любому из пп.1-5, где антителом к IL-6-рецептору является рекомбинантное антитело. ! 8. Терапевтический агент для мезотелиомы по п.5, где моноклональным антителом к IL-6-рецептору человека является антитело РМ-1. ! 9. Терапевтический агент для мезотелиомы по п.6, где моноклональным антителом к IL-6-рецептору мыши является антитело MR 16-1. ! 10. Терапевтический агент для мезотелиомы по любому из пп.4-6 и 8-9, где антителом к IL-6-рецептору является химерное антитело, гуманизированное антитело или человеческое антитело. ! 11. Терапевтический агент для мезотелиомы по п.7, где антителом к IL-6-рецептору является химерное антитело, гуманизированное антитело или человеческое антитело. ! 12. Терапевтический агент для мезотелиомы по п.10, где гуманизированным антителом к IL-6-рецептору является гуманизированное антитело РМ-1. ! 13. Терапевтический аген�
Claims (13)
1. Терапевтический агент для мезотелиомы, который содержит антитело к рецептору интерлейкина-6 (IL-6) в качестве его активного ингредиента.
2. Терапевтический агент для мезотелиомы по п.1, где мезотелиома является плевральной мезотелиомой.
3. Терапевтический агент для мезотелиомы по п.2, где плевральная мезотелиома является злокачественной плевральной мезотелиомой.
4. Терапевтический агент для мезотелиомы по п.1, где антителом к IL-6-рецептору является моноклональное антитело к IL-6-рецептору.
5. Терапевтический агент для мезотелиомы по п.1, где антителом к IL-6-рецептору является моноклональное антитело к IL-6-рецептору человека.
6. Терапевтический агент для мезотелиомы по п.1, где антителом к IL-6-рецептору является моноклональное антитело к IL-6-рецептору мыши.
7. Терапевтический агент для мезотелиомы по любому из пп.1-5, где антителом к IL-6-рецептору является рекомбинантное антитело.
8. Терапевтический агент для мезотелиомы по п.5, где моноклональным антителом к IL-6-рецептору человека является антитело РМ-1.
9. Терапевтический агент для мезотелиомы по п.6, где моноклональным антителом к IL-6-рецептору мыши является антитело MR 16-1.
10. Терапевтический агент для мезотелиомы по любому из пп.4-6 и 8-9, где антителом к IL-6-рецептору является химерное антитело, гуманизированное антитело или человеческое антитело.
11. Терапевтический агент для мезотелиомы по п.7, где антителом к IL-6-рецептору является химерное антитело, гуманизированное антитело или человеческое антитело.
12. Терапевтический агент для мезотелиомы по п.10, где гуманизированным антителом к IL-6-рецептору является гуманизированное антитело РМ-1.
13. Терапевтический агент для мезотелиомы по п.11, где гуманизированным антителом к IL-6-рецептору является гуманизированное антитело РМ-1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003-358152 | 2003-10-17 | ||
| JP2003358152 | 2003-10-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006116896/15A Division RU2392967C2 (ru) | 2003-10-17 | 2004-10-15 | Терапевтический агент для мезотелиомы |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010102911A true RU2010102911A (ru) | 2011-08-10 |
| RU2554942C2 RU2554942C2 (ru) | 2015-07-10 |
Family
ID=34463281
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006116896/15A RU2392967C2 (ru) | 2003-10-17 | 2004-10-15 | Терапевтический агент для мезотелиомы |
| RU2010102911/15A RU2554942C2 (ru) | 2003-10-17 | 2004-10-15 | Терапевтический агент для мезотелиомы |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006116896/15A RU2392967C2 (ru) | 2003-10-17 | 2004-10-15 | Терапевтический агент для мезотелиомы |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20070134242A1 (ru) |
| EP (1) | EP1690550B1 (ru) |
| JP (1) | JP4651541B2 (ru) |
| KR (1) | KR101193708B1 (ru) |
| CN (1) | CN1874790B (ru) |
| AR (1) | AR046290A1 (ru) |
| AU (1) | AU2004281139B2 (ru) |
| BR (1) | BRPI0415505A (ru) |
| CA (1) | CA2542691C (ru) |
| DK (1) | DK1690550T3 (ru) |
| ES (1) | ES2392824T3 (ru) |
| HK (1) | HK1096588A1 (ru) |
| IL (1) | IL174909A (ru) |
| MX (1) | MXPA06003768A (ru) |
| MY (1) | MY149856A (ru) |
| NO (1) | NO20061906L (ru) |
| NZ (1) | NZ546557A (ru) |
| PL (1) | PL1690550T3 (ru) |
| RU (2) | RU2392967C2 (ru) |
| SI (1) | SI1690550T1 (ru) |
| TW (1) | TWI350175B (ru) |
| WO (1) | WO2005037315A1 (ru) |
| ZA (1) | ZA200602973B (ru) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE547119T1 (de) | 1997-03-21 | 2012-03-15 | Chugai Pharmaceutical Co Ltd | Präventives oder therapeutisches mittel mit einem il-6-antagonisten als wirkstoff für durch sensibilisierte t-zellen vermittelte erkrankungen |
| UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| EP3578168A1 (en) | 2002-02-14 | 2019-12-11 | Chugai Seiyaku Kabushiki Kaisha | Formulation of antibody-containing solutions comprising a sugar as a stabilizer |
| GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| JPWO2005090405A1 (ja) | 2004-03-24 | 2008-04-17 | 中外製薬株式会社 | インターロイキン−６受容体に対するヒト型化抗体のサブタイプ |
| EP1941907B1 (en) | 2005-10-14 | 2016-03-23 | Fukuoka University | Inhibitor of transplanted islet dysfunction in islet transplantation |
| KR101239051B1 (ko) | 2005-10-21 | 2013-03-04 | 추가이 세이야쿠 가부시키가이샤 | 심장질환 치료제 |
| AR057582A1 (es) * | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| CN101370521A (zh) * | 2006-01-27 | 2009-02-18 | 学校法人庆应义塾 | 伴有脉络膜血管生成的疾病的治疗药 |
| JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
| CA2648644C (en) | 2006-04-07 | 2016-01-05 | Osaka University | Muscle regeneration promoter |
| CN101646459B (zh) * | 2007-01-23 | 2014-02-12 | 国立大学法人信州大学 | 慢性排斥反应抑制剂 |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| AU2008254578B2 (en) * | 2007-05-21 | 2013-06-06 | Alderbio Holdings Llc | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| NZ597767A (en) | 2007-05-21 | 2013-06-28 | Bristol Myers Squibb Co | Antibodies to IL-6 and use thereof |
| US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| KR102225009B1 (ko) | 2007-09-26 | 2021-03-08 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| JP5334319B2 (ja) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法 |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| KR20220162801A (ko) | 2008-04-11 | 2022-12-08 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| WO2009148148A1 (ja) * | 2008-06-05 | 2009-12-10 | 国立がんセンター総長が代表する日本国 | 神経浸潤抑制剤 |
| JP5551593B2 (ja) * | 2008-07-30 | 2014-07-16 | 国立大学法人 岡山大学 | 新規悪性中皮腫治療剤及び免疫賦活化剤 |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| MX2011005408A (es) * | 2008-11-25 | 2011-06-16 | Alder Biopharmaceuticals Inc | Antagonistas de il-6 para prevenir o tratar la trombosis. |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| AU2010278067B2 (en) * | 2009-07-31 | 2016-10-27 | Shin Maeda | Cancer metastasis inhibitor |
| ES2622366T3 (es) | 2009-10-26 | 2017-07-06 | F. Hoffmann-La Roche Ag | Procedimiento para la producción de una inmunoglobulina glucosilada |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| EP2504030A4 (en) | 2009-11-24 | 2013-06-26 | Alderbio Holdings Llc | IL-6 ANTAGONISTS FOR INCREASING ALBUMIN AND / OR REDUCING CRP |
| TWI505838B (zh) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
| HRP20221490T1 (hr) * | 2010-05-28 | 2023-02-03 | Chugai Seiyaku Kabushiki Kaisha | Poboljšanje antitumorskog odgovora t stanice |
| US20130123138A1 (en) * | 2010-07-25 | 2013-05-16 | New York University | Compositions and methods for prognosis of mesothelioma |
| EP3351559A3 (en) | 2010-11-08 | 2018-10-31 | F. Hoffmann-La Roche AG | Subcutaneously administered anti-il-6 receptor antibody |
| DK2643018T3 (da) | 2010-11-23 | 2021-01-18 | Vitaeris Inc | Anti-il-6-antistoffer til behandling af oral mucositis |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| MX342810B (es) * | 2011-03-03 | 2016-10-13 | Apexigen Inc | Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso. |
| ES2880291T3 (es) | 2011-06-02 | 2021-11-24 | Univ Louisville Res Found Inc | Nanopartículas conjugadas a un agente antinucleolina |
| MX339762B (es) | 2011-09-28 | 2016-05-27 | Univ Autonoma Del Estado De Morelos | Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen. |
| JO3370B1 (ar) | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
| WO2014088040A1 (ja) | 2012-12-06 | 2014-06-12 | 国立大学法人 金沢大学 | 中皮腫の治療方法 |
| EP3009518B1 (en) | 2013-06-11 | 2020-08-12 | National Center of Neurology and Psychiatry | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy |
| RU2674996C2 (ru) | 2013-07-04 | 2018-12-14 | Ф. Хоффманн-Ля Рош Аг | Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки |
| EP4269440A3 (en) | 2015-02-27 | 2024-02-28 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
| WO2016179394A1 (en) | 2015-05-05 | 2016-11-10 | Malik Mohammad Tariq | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents |
| WO2016186154A1 (ja) | 2015-05-19 | 2016-11-24 | 国立研究開発法人国立精神・神経医療研究センター | 多発性硬化症（ｍｓ）患者の新規治療適用判断方法 |
| US11484591B2 (en) | 2016-02-22 | 2022-11-01 | Ohio State Innovation Foundation | Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites |
| WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
| EP3596175A4 (en) | 2017-03-17 | 2021-01-13 | The Ohio State Innovation Foundation | NANOPARTICLE FOR THE DELIVERY OF CHEMOPREVENTIVE AGENTS |
| US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
| KR20200074160A (ko) | 2017-10-20 | 2020-06-24 | 가꼬우호우징 효고 이카다이가쿠 | 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물 |
| WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US521628A (en) | 1894-06-19 | Housekeeping-cabinet | ||
| US5670373A (en) * | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
| JP2914672B2 (ja) | 1989-01-17 | 1999-07-05 | 中外製薬株式会社 | Ｂｓｆ▲下２▼アンタゴニスト |
| JP2998976B2 (ja) * | 1989-07-20 | 2000-01-17 | 忠三 岸本 | ヒトインタ―ロイキン―６レセプターに対する抗体 |
| JP2898040B2 (ja) | 1990-01-26 | 1999-05-31 | 忠三 岸本 | ｇｐ１３０蛋白質に対する抗体 |
| US5210075A (en) | 1990-02-16 | 1993-05-11 | Tanabe Seiyaku Co., Ltd. | Interleukin 6 antagonist peptides |
| US5795965A (en) | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| FR2694767B1 (fr) | 1992-08-13 | 1994-10-21 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
| US5888510A (en) * | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| AU7967294A (en) | 1993-10-06 | 1995-05-01 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
| JPH07324097A (ja) | 1994-05-30 | 1995-12-12 | Daicel Chem Ind Ltd | インターロイキン６拮抗剤、及びペプチド類または医薬として許容されるその塩類 |
| RU2147442C1 (ru) | 1994-10-21 | 2000-04-20 | Кисимото Тадамицу | Фармацевтическая композиция для профилактики или лечения заболеваний, вызываемых образованием il-6 |
| IT1274350B (it) | 1994-12-06 | 1997-07-17 | Angeletti P Ist Richerche Bio | Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130 |
| IT1274782B (it) | 1994-12-14 | 1997-07-24 | Angeletti P Ist Richerche Bio | Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130 |
| JPH08245414A (ja) * | 1995-01-27 | 1996-09-24 | Private Biolog Corp | Ｉｌ−６関連疾患の治療用組成物および方法 |
| FR2733250B1 (fr) | 1995-04-21 | 1997-07-04 | Diaclone | Anticorps monoclonaux anti-gp130, et leurs utilisations |
| JPH08311098A (ja) | 1995-05-22 | 1996-11-26 | Daicel Chem Ind Ltd | 新規ペプチド類およびそれを含有するインターロイキン６拮抗剤 |
| US5571513A (en) | 1995-05-31 | 1996-11-05 | The Board Of Regents Of The University Of Oklahoma | Anti-gp130 monoclonal antibodies |
| AU6038196A (en) * | 1995-06-07 | 1996-12-30 | Private Biologicals Corporation | Compositions and methods of treating il-6 associated disease s |
| US20020187150A1 (en) * | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
| DE69937994T2 (de) * | 1998-03-17 | 2008-12-24 | Chugai Seiyaku K.K. | Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper |
| AU2066301A (en) | 1999-12-09 | 2001-06-18 | Human Genome Sciences, Inc. | Il-6 like polynucleotide |
| DE60133029T2 (de) | 2000-10-25 | 2009-03-12 | Chugai Seiyaku K.K. | Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff |
| AU2000279625A1 (en) * | 2000-10-27 | 2002-05-15 | Chugai Seiyaku Kabushiki Kaisha | Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient |
| UA80091C2 (en) * | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| US20050090453A1 (en) * | 2003-01-15 | 2005-04-28 | Solbec Pharmaceuticals Co., Ltd. | Methods of modulating IL-6 |
| AU2004204261A1 (en) * | 2003-01-15 | 2004-07-29 | Solbec Pharmaceuticals Limited | Method of modulating IL-6 |
| EP1594897A4 (en) * | 2003-02-04 | 2006-11-08 | Centocor Inc | USE OF IL-6 ANTAGONISTS IN COMBINATION WITH STEROIDS FOR INCREASED APOPTOSIS |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| US20060094645A1 (en) * | 2004-10-06 | 2006-05-04 | Oliver Lawless | Method for defining and treating chemically-induced immune disorders using tumor necrosis factor (TFNalpha), interleukin-1 (lL-1), and interleulin-6R(lL-6R) antagonists |
-
2004
- 2004-10-15 EP EP04792816A patent/EP1690550B1/en active Active
- 2004-10-15 CN CN200480031888XA patent/CN1874790B/zh not_active Expired - Fee Related
- 2004-10-15 JP JP2005514876A patent/JP4651541B2/ja active Active
- 2004-10-15 NZ NZ546557A patent/NZ546557A/en not_active IP Right Cessation
- 2004-10-15 MX MXPA06003768A patent/MXPA06003768A/es active IP Right Grant
- 2004-10-15 TW TW093131346A patent/TWI350175B/zh not_active IP Right Cessation
- 2004-10-15 MY MYPI20044273A patent/MY149856A/en unknown
- 2004-10-15 AR ARP040103743A patent/AR046290A1/es unknown
- 2004-10-15 WO PCT/JP2004/015674 patent/WO2005037315A1/ja active Application Filing
- 2004-10-15 DK DK04792816.3T patent/DK1690550T3/da active
- 2004-10-15 PL PL04792816T patent/PL1690550T3/pl unknown
- 2004-10-15 SI SI200431946T patent/SI1690550T1/sl unknown
- 2004-10-15 CA CA2542691A patent/CA2542691C/en not_active Expired - Fee Related
- 2004-10-15 RU RU2006116896/15A patent/RU2392967C2/ru not_active IP Right Cessation
- 2004-10-15 AU AU2004281139A patent/AU2004281139B2/en not_active Ceased
- 2004-10-15 US US10/575,455 patent/US20070134242A1/en not_active Abandoned
- 2004-10-15 BR BRPI0415505-0A patent/BRPI0415505A/pt not_active IP Right Cessation
- 2004-10-15 KR KR1020067007246A patent/KR101193708B1/ko not_active IP Right Cessation
- 2004-10-15 RU RU2010102911/15A patent/RU2554942C2/ru not_active IP Right Cessation
- 2004-10-15 ES ES04792816T patent/ES2392824T3/es active Active
-
2006
- 2006-04-10 IL IL174909A patent/IL174909A/en not_active IP Right Cessation
- 2006-04-12 ZA ZA200602973A patent/ZA200602973B/en unknown
- 2006-04-28 NO NO20061906A patent/NO20061906L/no not_active Application Discontinuation
-
2007
- 2007-02-09 HK HK07101545.1A patent/HK1096588A1/xx not_active IP Right Cessation
-
2008
- 2008-04-10 US US12/081,126 patent/US8802092B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010102911A (ru) | Терапевтический агент для мезотелиомы | |
| RU2010117171A (ru) | Терапевтические средства, используемые против реакции трансплантант против хозяина, содержащие в качестве активного ингредиента ингибитор рецептора интерлейкина-6 | |
| HUP0303952A2 (hu) | Terápiás ágens gyermekkori krónikus artrítiszhez hasonló betegségekre | |
| RU97108070A (ru) | Фармацевтическая композиция для профилактики или лечения заболеваний, вызываемых образование il-6 | |
| EA201300022A1 (ru) | Терапевтическое человеческое моноклональное антитело против il-1r1 | |
| NZ568769A (en) | Human monoclonal antibodies against CD20 | |
| ATE180511T1 (de) | Humanisierter b-b10, ein anti-il-2-rezeptor- antikörper | |
| RU2009131747A (ru) | Ингибитор хронического отторжения | |
| DK0616537T3 (da) | CDw52-specifikt antistof til behandling af dissemineret sclerose | |
| NO20054959D0 (no) | Fremgangsmater for behandling av interleukin-6 relaterte sykdommer | |
| AU9399501A (en) | Therapeutic antibodies | |
| EA200301215A1 (ru) | Лиганды рецепторов 5-ht и их применение | |
| ES2291311T3 (es) | 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidores de proteina quinasas. | |
| BR0315123A (pt) | Composições farmacêuticas direcionadas a receptores erb-b1 | |
| HUP0402653A2 (hu) | Interleukin 15-re (IL-15-re) specifikus emberi antitestek | |
| ATE428731T1 (de) | Therapeutische antiköper mit reduzierten nebenwirkungen | |
| EP0791359A4 (en) | MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES | |
| DK0578774T3 (da) | Monoklonale antistoffer mod stamcellefaktor-receptorer | |
| EE200100667A (et) | CD20 vastaste antikehade kasutamine transplantaadi peremehevastase reaktsiooni raviks | |
| DK0804236T3 (da) | Anvendelse af anti-TNF-antistoffer som lægemidler til behandling af sygdomme, som involverer forhøjede interleukin-6-serumniveauer | |
| IL190693A (en) | Substance damage suppressants are implanted after islet transplantation, containing and utilizing antibodies that detect il-6 receptor. | |
| DK1257584T3 (da) | Humaniserede antistoffer, som sekvestrerer | |
| DK1406656T3 (da) | Fremgangsmåder til administrering af anti-TNF-alfa-antistoffer | |
| BRPI0412245A (pt) | anticorpos de rg1 e usos destes | |
| DK1734995T3 (da) | Monoklonale antistoffer og hepatocyytvækstfaktor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20181016 |